Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
Needham & Company Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:41 AM ESTNeedham & Company initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $17.00.
Analyst Elliot Wilbur commented, "We initiate coverage of Neothetics (NEOT), a clinical-stage specialty pharma company focused on developing and commercializing innovative and differentiated... More
Guggenheim Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:04 AM ESTGuggenheim initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $16.00.
Analyst Louise Chen highlighted the company's two products in development:
LIPO-202 (Salmeterol Xinafoate for Injection): Injectable designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate): Orphan designation for treatment of... More